0001213900-20-045804.txt : 20201231
0001213900-20-045804.hdr.sgml : 20201231
20201231172216
ACCESSION NUMBER: 0001213900-20-045804
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201229
FILED AS OF DATE: 20201231
DATE AS OF CHANGE: 20201231
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rubini Jonathan Brian
CENTRAL INDEX KEY: 0001723667
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-52545
FILM NUMBER: 201429493
MAIL ADDRESS:
STREET 1: 2655 MARSTON DRIVE
CITY: ANCHORAGE
STATE: AK
ZIP: 99517
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Wize Pharma, Inc.
CENTRAL INDEX KEY: 0001218683
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 880445167
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 24 HANAGAR ST
CITY: HOD HASHARON
STATE: L3
ZIP: 4527713
BUSINESS PHONE: 972 472 260 0536
MAIL ADDRESS:
STREET 1: 24 HANAGAR ST
CITY: HOD HASHARON
STATE: L3
ZIP: 4527713
FORMER COMPANY:
FORMER CONFORMED NAME: OphthaliX, Inc.
DATE OF NAME CHANGE: 20120207
FORMER COMPANY:
FORMER CONFORMED NAME: DENALI CONCRETE MANAGEMENT INC
DATE OF NAME CHANGE: 20030213
4
1
ownership.xml
X0306
4
2020-12-29
0
0001218683
Wize Pharma, Inc.
WIZP
0001723667
Rubini Jonathan Brian
C/O WIZE PHARMA, INC.
24 HANAGAR STREET
HOD HASHARON
L3
4527708
ISRAEL
0
0
1
0
Common Stock
2020-12-29
4
X
0
4074074
A
6529813
D
Common Stock
2020-12-29
4
S
0
33951
D
6495862
D
Common Stock
2020-12-29
4
X
0
350000
A
6845862
D
Common Stock
2020-12-29
4
S
0
2692
D
6843170
D
Common Stock
2020-12-29
4
X
0
259037
A
7102207
D
Common Stock
2020-12-29
4
S
0
2159
D
7100048
D
Warrant (right to buy)
0.27
2020-12-29
4
X
0
4074074
0
D
2024-12-19
Common Stock
4074074
0
D
Warrant (right to buy)
0.16
2020-12-29
4
X
0
350000
0
D
2019-04-21
2023-10-23
Common Stock
350000
0
D
Warrant (right to buy)
1.97
2020-12-29
4
X
0
259037
0
D
2017-11-16
2020-12-31
Common Stock
259037
0
D
On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.
On December 29, 2020 the reporting person exercised a warrant to purchase 4,074,074 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 33,951 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 4,040,123 shares.
On December 29, 2020 the reporting person exercised a warrant to purchase 350,000 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 2,692 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 347,308 shares.
On December 29, 2020 the reporting person exercised a warrant to purchase 259,037 shares of the registrant's common stock for $1.97 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 2,159 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 256,878 shares.
Exercisable five days following the public announcement of positive clinical data results for LO2A.
The expiration date was extended from 11/16/2029 to 12/31/2020.
/s/ Jonathan Rubini
2020-12-31